KRTAP4-2

Across TCGA pan-cancer cohorts, KRTAP4-2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRTAP4-2 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KRTAP4-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP4-2 expression acts as an unfavorable survival marker.

HNSC, COAD, and LGG are the cancer types where KRTAP4-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.130	0.696	.001	36	view →
COAD	OS	Median	All	0.112	0.670	<.001	21	view →
LGG	DFS	Median	All	0.179	0.834	<.001	12	view →
SARC	DFS	Median	All	0.109	0.611	.030	6	view →
LIHC	DFS	Median	All	0.148	0.544	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRTAP4-2–HNSC (DFS)

Open the HNSC breakdown →